Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10029


RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This phase II trial is studying how well giving alemtuzumab together with tacrolimus and methylprednisolone works in treating acute graft-versus-host disease in patients who have undergone donor stem cell transplant.

Study summary:

OBJECTIVES: Primary - Determine the 4-week rate of complete response in patients with severe acute graft-vs-host disease (GVHD) treated with alemtuzumab, tacrolimus, and methylprednisolone within 100 days after undergoing allogeneic stem cell transplantation. Secondary - Determine the best response at 4 and 12 weeks in patients treated with this regimen. - Determine 6-month survival of patients treated with this regimen. - Determine the rate of infectious complications in patients treated with this regimen. - Determine rate of chronic GVHD in patients treated with this regimen. OUTLINE: This is an open-label, single-blind, multicenter study. Patients receive methylprednisolone IV on days 1-3 and then orally or IV on days 4-14; tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease; and alemtuzumab IV over 2 hours on days 4-6, 18, and 32. Treatment continues in the absence of unacceptable toxicity or the development of serious infection. After completion of study treatment, patients are followed at 2 and 4 weeks. PROJECTED ACCRUAL: A total of 9-34 patients will be accrued for this study within 8-12 months.


DISEASE CHARACTERISTICS: - Diagnosis of acute graft-vs-host disease (GVHD) - Clinical grade C or D disease - No grade C disease with single organ skin involvement - Has undergone allogeneic stem cell transplantation within the past 100 days - Absolute neutrophil count > 500/mm^3 (donor-derived [> 60% by peripheral blood lymphocyte chimerism analyses]) - No development of GVHD after prior donor lymphocyte infusion - Must have received prior prophylactic cyclosporine or tacrolimus at the onset of acute GVHD PATIENT CHARACTERISTICS: Age - Over 18 Performance status - Not specified Life expectancy - Not specified Hematopoietic - See Disease Characteristics Hepatic - No serologic evidence of active hepatitis B or C infection Renal - Creatinine ≤ 3.5 mg/dL - No requirement for dialysis Cardiovascular - No requirement for vasopressors Pulmonary - No requirement for a ventilator Other - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception during and for 6 months after completion of study treatment - No known HIV positivity - No active uncontrolled infection - No other organ dysfunction PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

Campath-1H + FK506 and Methylprednisolone for GVHD

Official Title:

Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease

Overall Status:


Study Phase:

Phase 2



Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Case Comprehensive Cancer Center

Oversight Authority:

United States: Federal Government

Reasons Why Stopped:

Study Type:


Study Design:

Endpoint Classification: Efficacy Study, Interven

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Mary Laughlin, MD
Principal Investigator
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

Study Dates

Start Date:January 2005
Completion Date:May 2007
Completion Type:Actual
Primary Completion Date:June 2006
Primary Completion Type:Actual
Verification Date:June 2010
Last Changed Date:June 10, 2010
First Received Date:May 3, 2005

Study Outcomes

Outcome Type:Primary Outcome
Measure:Graft-vs-host disease response
Time Frame:1, 2, 3, and 4 months
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Incidence of serious infections by clinical, radiologic, and microbiologic assessments
Time Frame:1,2,3, and 4 months
Safety Issues:False

Study Interventions

Intervention Type:Biological
Description:alemtuzumab IV over 2 hours on days 4-6, 18, and 32
Intervention Type:Drug
Description:methylprednisolone IV on days 1-3 and then orally or IV on days 4-14
Intervention Type:Drug
Description:tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Case Comprehensive Cancer Center
Agency Class:NIH
Agency Type:Collaborator
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.